Roche Venture Fund — Full Portfolio

Enliven Therapeutics is a clinical-stage biopharmaceutical company that discovers and develops small molecule therapeutics using a precision medicine approach, with a focus on oncology and hematology.

BiotechHealthtechBoulder, US

Sam Kintz(Co-founder and Head of Pipeline)inJoe Lyssikatos(Co-founder and Research Fellow)Anish Patel(Co-founder and Chief Operating Officer)Rick Fair(Chief Executive Officer and Member of the Board of Directors)inHCHelen Collins(Chief Medical Officer)inBHBen Hohl(Chief Financial Officer and Head of Corporate Development)in

Co-investors5A5AM VenturesOROrbiMedPFPfizer Venture InvestmentsARARCH Venture PartnersBABay City CapitalJAJanus Henderson Investors+2 more

Entrada Therapeutics is a biotech company developing intracellular therapeutics based on its proprietary EEV Platform, aimed at reaching previously inaccessible or undruggable disease-causing targets inside cells.

BiotechHealthtechBoston, US

NSNatarajan Sethuraman(Executive Officer)inNKNerissa Kreher(Executive Officer)inKWKory Wentworth(Executive Officer)inDDDipal Doshi(Chief Executive Officer)inNatarajan Sethuraman, PhD(President of Research and Development)NJNathan J. Dowden(President and Chief Operating Officer)in

Co-investors5A5AM VenturesAGAgent CapitalMPMPM BioImpactMRMRL Ventures FundTCTCG CrossoverWEWellington Management

Freenome develops early-stage cancer detection technology using blood tests to identify cancer in its earliest, most treatable phases.

AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesLondon, US

RERiley Ennis(Founder)inCharles Roberts(Founder)inGOGabriel Otte(Founder)inAdam Stone(Chief Executive Officer and Director)Michael Altman(Chief Business Officer and Director)Shmuel (Sam) M. Cohn(Chief Financial Officer)

Co-investorsRARA CapitalAGAgent CapitalAMAME Cloud VenturesANAndreessen HorowitzARArtis VenturesASAsset Management Company+15 more

IDEAYA is a precision medicine oncology company developing first-in-class targeted therapies and rational drug combinations for molecularly defined, hard-to-treat cancers.

BiotechDigital HealthHealthtechMedical DevicesSouth San Francisco, US

PSPaul Stone(Executive Officer)inYujiro S. Hata(President, Chief Executive Officer and Director)

BoardTSTimothy Shannon(Director)inJDJohn Diekman(Director)inTRTerry Rosen(Director)JSJeffrey Stein(Director)

Co-investors5A5AM VenturesCACanaan PartnersGVGV (Google Ventures)NENextech InvestBIBiotechnology Value FundWUWuXi Healthcare Ventures

Jasper Therapeutics develops briquilimab, a targeted anti-KIT monoclonal antibody designed to deplete mast cells for treating chronic immunological and inflammatory diseases.

BiotechHealthtechRedwood City, US

Judith Shizuru(Director)HCHerb Cross(Executive Officer)inJMJeet Mahal(Executive Officer, Director)inPCPatrick Crutcher(Director)SLSvetlana Lucas(Director)Wenru Song(Executive Officer)

Co-investorsAVAvego BioScience CapitalQIQiming Venture Partners USATSTSVCABAbingworthIKIkarian Capital

miRagen Therapeutics is a biopharmaceutical company developing monoclonal antibodies and other engineered protein therapeutics targeting specific receptors (IGF-1R, FcRn, and TSHR) for autoimmune and rare diseases including thyroid eye disease, Graves' disease, and various autoimmune conditions.

BiotechHealthtechBoulder, US

William S. Marshall(Executive Officer, Director)Jason A. Leverone(Executive Officer)inDavid Rodman(Executive Officer)Stephen Mahoney(President, Chief Executive Officer and Director)Thomas Beetham(Chief Operating Officer)inRadhika Tripuraneni(Chief Medical Officer)in

Co-investorsBRBrace PharmaBRBroadview VenturesJAJAFCO GroupMCMC Healthcare VenturesRIRidgeback CapitalATAtlas Venture+3 more

Senseonics develops and commercializes Eversense, an implantable continuous glucose monitoring system designed to measure blood sugar levels for up to one year in people with diabetes, offering an alternative to conventional glucose monitors that require more frequent sensor replacement.

BiotechGermantown, US

Mukul Jain(Executive Officer)FRFrancine R. Kaufman(Executive Officer, Director)inRSRick Sullivan(Executive Officer)inKenneth L Horton(Executive Officer)TTTimothy T. Goodnow(Executive Officer, Director)Mirasol Panlilio(Executive Officer)in

Co-investorsNENew Enterprise Associates (NEA)VEVensana Capital

Vaxcyte is a biotech company developing vaccines to treat or prevent serious infectious diseases.

BiotechDeep TechHealthtechSouth San Francisco, US

Grant Pickering(Chief Executive Officer, Director and Co-Founder)Jeff Fairman(Vice President of Research and Co-Founder)Ashish Khanna(Executive Officer)

BoardTracy Saxton(Director)William Newell(Director)KVKurt von Emster(Director)in

Co-investorsABAbingworthCTCTI Life Sciences Fund L.P.FOForesite CapitalFRFrazier Life SciencesJAJanus Henderson InvestorsLOLongitude Capital+4 more

Tango Therapeutics develops genetically targeted medicines using synthetic lethality principles to treat specific tumors.

BiotechBoston, US

AHAlan Huang(Executive Officer)inACAdam Crystal(Executive Officer)inDBDaniella Beckman(Executive Officer)inDouglas Barry(Executive Officer)Aaron Davis(Director)

BoardBWBarbara Weber(Executive Officer, Director)in

Co-investorsFOForesite CapitalNENextech InvestNSNSG VenturesTHThird Rock Ventures

COUR develops antigen-specific immunotherapies that reprogram the immune system to treat the underlying causes of autoimmune and immune-mediated diseases while preserving normal immune function.

BiotechHealthtech

Co-investorsALAlpha Wave GlobalLULumira VenturesANAngelini VenturesJDJDRF T1D Fund

DiogenX is a preclinical-stage biotech company developing biologic therapeutics aimed at restoring insulin-producing beta cells for people with Type 1 diabetes.

BiotechDeep TechDigital HealthHealthtechMarseille, FR

BCBenjamin Charles(Co-Founder & CEO)inPCPatrick Collombat(Co-Founder & Scientific Advisor)inJean-Pascal Tranié(Co-Founder)in

Co-investorsADAdBio partnersBOBoehringer Ingelheim Venture FundSUSunstone CapitalJDJDRF T1D FundOMOmnes Capital

Komed Health provides a secure, real-time communication platform designed for hospitals to enhance collaboration among care teams and improve patient care delivery.

Digital HealthEnterprise SoftwareHealthtechSaaSZurich, CH

Marc(Technical Co-founder)

Co-investorsSISICTIC

Soteria Biotherapeutics develops protein-based biotherapeutics and small molecules using its LITE Switch technology platform for drug discovery and development across oncology, immune-oncology, and inflammatory disease indications.

BiotechDeep TechHealthtechMedical DevicesWellness & FitnessSan Francisco, US

Jim Wells(Co-founder, Scientific Advisory Board Chair)KMKristine M Ball(Executive Officer, Director)inZHZachary Hill(Executive Officer, Director)in

BoardNisha Marathe(Director)DADavid Allison(Director)inKGKeno Gutierrez(Director)in

Co-investors5A5AM VenturesNONovartis Venture FundVEVersant VenturesBIBioGeneration VenturesWEWestlake Village BioPartners

SpliceBio develops genetic medicines using a proprietary protein splicing platform to treat diseases caused by mutations in large genes.

BiotechDeep TechDigital HealthBarcelona, ES

DVDr. Vila-Perelló(CEO)Dr. Frutos(Co-founder)Miquel Vila-Perelló, Ph.D(Co-Founder & CEO)Silvia Frutos, Ph.D(Co-Founder & CTO)

Co-investorsASAsabys PartnersNONovartis Venture FundSASanofi VenturesYSYsios CapitalCRCriteria Bio VenturesNENew Enterprise Associates (NEA)+3 more

Vivet Therapeutics is a clinical-stage biotechnology company developing recombinant adeno-associated virus (rAAV) gene therapies for rare, inherited metabolic diseases, including Wilson's Disease and cerebrotendinous xanthomatosis.

BiotechHealthtechParis, FR

Co-investorsHEHealthCapKUKurma PartnersNONovartis Venture FundYSYsios CapitalCOColumbus Venture PartnersEUEurazeo+1 more

BiotechWatertown, US

Edward Mascioli(Executive Officer)Andrew Myers(Director)

BoardMarkus Goebel(Director)HSHenry Skinner(Director)inVikas Goyal(Director)RPRaj Parekh(Director)in

Board seatAHAnja Harmeier· per SEC Form D · $20M raise · filed Mar 2018

Co-investorsADAdvent Life SciencesGUGurnet Point CapitalNONovartis Venture Fund

23andMe operates a research platform that collects genetic data from millions of users to advance genomic research and health discovery.

BiotechDigital HealthDirect to ConsumerHealthtechLongevityMountain View, US

AWAnne Wojcicki(Founder)inLinda Avey(Founder)Paul Cheung(Co-founder)Andrew Page(Executive Officer, Director)KHKathy Hibbs(Executive Officer)inPaul Cusenza(Founder)

Co-investorsADAdam NashALAllied Venture PartnersBRBright Success CapitalCACasdin CapitalCICivilization Ventures Management, LlcEQEQUIAM+21 more

Aligos is a clinical-stage biotechnology company developing therapeutics for liver and viral diseases, including chronic hepatitis B virus (HBV) infection and MASLD/MASH.

BiotechHealthtechSouth San Francisco, US

Leonid Beigelman(President)inLMLawrence M. Blatt(Chairman, President, & Chief Executive Officer; co-founder)inHAHardean Achneck(Executive Officer)inBDBrian Dowd(Executive Vice President - Controller)inLucinda Quan(Executive Vice President - General Counsel)inJSJulian Symons(Executive Vice President, Chief Scientific Officer)in

Co-investorsPIPivotal Life SciencesWEWellington ManagementVIVivo Capital

Portfolio company that completed a successful 2018 biotech IPO, resulting in a 9x return for RiverVest.

BiotechSan Carlos, US

Nenad Tomasevic(Executive Officer)Christopher Bebbington(Executive Officer, Director)Alejandro Dorenbaum(Executive Officer)

BoardFCFarah Champsi(Director)inJMJohn McKearn(Director)inPeter Moldt(Director)

Co-investorsALAlta PartnersLILifeSci Venture PartnersNENew Enterprise Associates (NEA)RIRiverVest Venture PartnersSASamsara BioCapital

Co-investorsAVAvego BioScience CapitalBIBioGenerator VenturesPEPerot JainRIRiverVest Venture PartnersSRSR One Capital Management

PBM Capital is an investment firm that provides funding and operational support to scientists and entrepreneurs, helping them bring products to market and grow their businesses.

BiotechHealthtechBannockburn, US

Brian Kaspar(Executive Officer, Director)James L'Italien(Executive Officer)Andrew F. Knudten(Executive Officer)Sukumar Nagendran(Executive Officer)Thomas Dee(Executive Officer)Sean Nolan(Executive Officer, Director)

Co-investorsFOForesite CapitalPBPBM CapitalRARA CapitalSOSofinnova VenturesDEDeerfield Management Company

Biometric smart gun with fingerprint and facial recognition

KKKai Kloepfer(Founder)in

Co-investorsBRBreak Trail VenturesCACathexis VenturesDRDraper AssociatesGAGaingelsNANat Turner1010X Capital+3 more

Blueprint Medicines is a biopharmaceutical company that discovers and develops targeted medicines for patients with diseases such as gastrointestinal stromal tumor and other conditions driven by genetic changes.

BiotechHealthtechCambridge, US

Nick Lydon(Director)CSChristoph S. Lengauer(Executive Officer)inChristine Bellon(Executive Officer)inKyle Kuvalanka(Executive Officer)in

BoardAlexis Borisy(Executive Officer, Director)Daniel Lynch(Director)

Co-investorsF-F-Prime CapitalFOForesite CapitalNENextech InvestRARA CapitalRIRidgeback CapitalWEWellington Management+1 more

Bonum Therapeutics develops antibody-controlled protein therapeutics that remain inactive until bound to their target, using a sensor-domain mechanism to deliver regulated, targeted activity.

BiotechHealthtechSeattle, US

JMJohn Mulligan(Executive Officer, Director, Promoter)inNPNeela Patel(Executive Officer)inDHDiane Hollenbaugh(Executive Officer)in

BoardSBSamuel Bjork(Director)inMSMonique Schiersing(Director)inJMJohn McKearn(Director)in

Co-investorsRIRiverVest Venture PartnersVIVivo Capital3X3x5 PartnersCOCodon CapitalDIDigitalis Ventures

Corvus Pharmaceuticals is a biopharmaceutical company developing immunology-focused medicines that target cellular components of the immune system, with therapeutic focus on immune diseases and cancer.

BiotechHealthtechBurlingame, US

RARichard A. Miller(President & CEO, Co-Founder)inLeiv Lea(Executive Officer)in

BoardElisha (Terry) P. Gould(Director)Peter Moldt(Director)PTPeter Thompson(Co-Founder)inTerry G. Gould(Director)

Co-investorsAVAvoro Capital AdvisorsFOForesite CapitalOROrbiMed

Gilead discovers, develops, and delivers innovative therapeutics for people with life-threatening diseases, focusing on virology, oncology, and inflammation across more than 35 countries.

BiotechDigital HealthHealthtechMedical DevicesFoster City, US

LLLou Lange(Founder)MLMichael L. Riordan(Founder)inDODaniel O'Dayin

Co-investorsAIAisling CapitalASAsset Management CompanyFRFrazier Life SciencesKLKleiner PerkinsLOLongitude CapitalLULumira Ventures+6 more

Enthera Srl is a privately held pharmaceutical company founded in 2016 and based in Milan, Italy.

BiotechHealthtechMilan, IT

Co-investorsSOSofinnova PartnersINIndaco Venture PartnersABAbbVieJDJDRF T1D Fund

Epibiologics develops protein degradation medicines using protein sciences and antibody engineering capabilities.

BiotechMedical DevicesSan Mateo, US

ALAnn Lee-Karlon(Executive Officer, Director)inMitchell Mutz(Executive Officer, Director)James Wells(Director)

BoardSBSamuel Bjork(Director)inACAlexandra Cantley(Director)inSMSeiji Miyahara(Director)in

Co-investorsAVAvego BioScience CapitalGVGV (Google Ventures)MIMission BiocapitalNONovartis Venture FundSASamsara BioCapitalTATaiho Ventures, LLC+4 more

Fabric Genomics provides an AI-based platform for next-generation sequencing (NGS) analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing.

AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesOakland, US

MRMartin Reese(Co-Founder, President, and CEO)inMRMartin Reese, Ph.D.(Co-Founder, President, and CEO)EFErwin Frise(Vice President of Technology and Data Science)in

Co-investorsARArtis VenturesFOForesite CapitalMIMighty CapitalCACasdin Capital

Flatiron Health combines AI-powered technology and clinical expertise with real-world oncology data to help healthcare providers and life science organizations improve cancer care and research.

AI & Machine LearningData & InfrastructureHealthtechMedical DevicesNew York, US

NTNat Turner(Founder)inZachary Weinberg(Director, Executive Officer)NHNathan Hubbard(Chief Executive Officer)inMBMichael Bierl(Chief Business Officer)inCBCal Brouilette(Chief Financial Officer)inACAllison Candido(Chief Technology Officer)in

Co-investorsBOBoxGroupCACarnrite VenturesFIFirst Round CapitalGRGreat Oaks Venture CapitalGVGV (Google Ventures)STStripes+8 more

Forcefield Therapeutics develops cardioprotective proteins for the treatment of cardiac disease, with an initial focus on myocardial infarction (heart attack).

BiotechHealthtechMedical Devices

JJohn

Foundation Medicine is a precision medicine company that develops comprehensive genomic profiling and companion diagnostic tests for cancer and other diseases.

BiotechDigital HealthMedical DevicesBoston, US

Alexis Borisy(Founder)Eric Lander(Founder)Levi Garraway(Founder)Todd Golub(Founder)Vera Grossmann(Interim Chief Executive Officer and Chief Operating Officer)in

Co-investorsGVGV (Google Ventures)KHKhosla VenturesKLKleiner PerkinsNSNSG VenturesRIRidgeback CapitalANAndreessen Horowitz+2 more

GlycoEra develops glycan-based therapeutics, applying glycoengineering technology to create biologic drugs.

BiotechHealthtechNewton, US

Ganesh V. Kaundinya(President & CEO)in

Co-investors5A5AM VenturesCACatalio Capital Management, LPLILifeArc VenturesSISixty Degree CapitalSOSofinnova PartnersAGAgent Capital+1 more

Portfolio company acquired by Roche.

BiotechSeattle, US

JMJohn Mulligan(Executive Officer, Director, Promoter)inMitchell Mutz(Director)Nicholas Walrod(Director)

BoardJMJohn McKearn(Director)inKarl Handelsman(Director)

Co-investorsDIDigitalis VenturesRIRiverVest Venture Partners3X3x5 PartnersCOCodon Capital

The National Kidney Foundation works to eliminate preventable kidney disease, accelerate innovation in patient care, and address structural inequities in kidney treatment and transplantation services.

HealthtechImpact & Social Good

Co-investorsYSYsios CapitalBIBioGeneration VenturesEPEpidarex CapitalSCScottish National Investment BankSOSofinnova Partners

Kumquat Biosciences is a biotech company developing small-molecule cancer therapeutics, combining drug discovery and clinical expertise to advance new oncology treatments.

BiotechSan Diego, US

Yi Liu(Executive Officer, Director)inYLYi Liu, Ph.D.(CEO)Lynn Yang(Director)

BoardCGCarl Gordon(Director)in

Co-investorsECEcoR1 CapitalOROrbiMed

Lino Biotech develops the MACS Matchmaker, a label-free binding-analysis platform based on focal molography that measures antibody and drug-candidate kinetics directly in complex biological samples such as serum, lysate, and plasma.

BiotechDeep TechHardware

Lumos Pharma is a clinical-stage biopharmaceutical company developing therapies for rare diseases, with a lead candidate targeting Pediatric Growth Hormone Deficiency.

BiotechHealthtechAustin, US

Richard John Hawkins(Executive Officer, Director)John C. McKew(President and Chief Scientific Officer)inP"Pisit "Duke" Pitukcheewanont(Chief Medical Officer)inLLLori Lawley(Chief Financial Officer)inBPBrad Powers(Chief Compliance Officer and General Counsel)inCMCampbell Murray(Executive Chairman)in

Co-investorsNENew Enterprise Associates (NEA)CLClarus VenturesDEDeerfield Management CompanySASante Health VenturesSASante VenturesWEWellcome Trust

Lysosomal Therapeutics Inc.

BiotechCambridge, US

Dimitri Krainc(Director)Robert Carpenter(Executive Officer, Director)Cornelis Been(Executive Officer, Director)

BoardSteven Hall(Director)Carole Nuechterlein(Director)inBernard Davitian(Director)

Co-investorsSASanofi VenturesATAtlas VentureHAHatteras Venture PartnersLILilly VenturesOMOmega Funds

Minoryx is a registration-stage biotech company developing novel therapies for severe, orphan genetic diseases of the central nervous system, with a lead compound (leriglitazone) in clinical trials for conditions including cerebral adrenoleukodystrophy, Friedreich's Ataxia, and Rett syndrome.

BiotechDeep TechHealthtechMedical DevicesMataró, ES

MMMarc Martinell(Co-Founder & Chief Executive Officer)in

Co-investorsCHChiesi VenturesCRCriteria Bio VenturesFUFund+INInvivo Capital PartnersKUKurma PartnersYSYsios Capital+5 more

Mironid is a drug development company building a pipeline of therapies targeting cAMP-degrading phosphodiesterase enzymes to treat Autosomal Dominant Polycystic Kidney Disease (ADPKD) and other rare kidney diseases.

BiotechMedical Devices

ARAdele Rowley(Chief Scientific Officer)in

Co-investorsBIBioGeneration VenturesEPEpidarex CapitalSOSofinnova PartnersSCScottish National Investment Bank

Mission Therapeutics develops therapeutics targeting deubiquitylating enzymes (DUBs), such as USP30, which regulate ubiquitylation and processes including mitophagy and protein homeostasis.

BiotechHealthtech

Co-investorsPFPfizer Venture InvestmentsRORosetta Capital Ltd.SOSofinnova PartnersSRSR One Capital ManagementIPIP Group

mySugr is a mobile app for diabetes management that allows users to log blood sugar levels, meals, and activity data, track patterns, and share reports with healthcare providers.

Digital HealthHealthtechWellness & Fitness

Co-investors191921 VenturesHAHansmann Family OfficePUPUSH Ventures

A biopharmaceutical company that discovers and develops medicines, building on immunology research to explore additional disease areas.

BiotechHealthtechMadison, US

JPJigar Patel(Executive Officer, Director)in

BoardRHRob Hart(Director)inDLDeval Lashkari(Director)in

Co-investorsTETelegraph Hill Partners

NMD Pharma is a clinical-stage biotech company developing first-in-class small-molecule therapies that selectively target skeletal muscle to treat rare neuromuscular diseases and age-related conditions.

BiotechDeep TechHealthtechMedical DevicesAarhus, DK

Co-investorsJEJeito CapitalNONovo HoldingsINInkefLULundbeckfonden Ventures

Noema Pharma develops a late-stage portfolio of oral small molecule therapeutics for people with neurological and related disorders, targeting both orphan and larger indications with significant unmet medical needs.

BiotechHealthtechMedical Devices

ILIlise Lombardo(Chief Executive Officer)inVKVolker Knappertz(Executive Vice President of Research & Development)inMSMichael Samar(Chief Financial Officer)inRLRob Lasser(Chief Medical Officer)in

Co-investorsBIBioMedPartnersJEJeito CapitalSOSofinnova PartnersEQEQTEQEQT Life SciencesFOForbion+3 more

Sarepta develops precision genetic medicines for people with rare diseases, with a focus on rare neuromuscular conditions.

BiotechHealthtechCambridge, US

WILLIAM CIAMBRONE(Executive Officer)DSDOUGLAS S. INGRAM(Executive Officer, Director)inDAVID TYRONNE HOWTON(Executive Officer)SANDESH MAHATME(Executive Officer)GILMORE O'NEILL(Executive Officer)ACALEXANDER CUMBO(Executive Officer)

Co-investorsAVAvoro Capital Advisors

Co-investorsLILifeforce CapitalPFPfizer Venture InvestmentsDIDigitalis VenturesLILightstone VenturesMOMorgenthalerSRSR One Capital Management

Soteria provides cybersecurity advisory services and solutions, including managed detection and response (MDR), virtual CISO support, domain monitoring, and Microsoft 365 risk management.

CybersecurityEnterprise SoftwareSaaSCharleston, US

GSGlenn Starkman(Co-Founder)inCHRISTOPHER O'ROURKE(Executive Officer)in

Co-investorsCHCheckmate Capital Group LLC5A5AM Ventures

Tempest Therapeutics is a clinical-stage biotechnology company developing in vivo CAR-T cell therapies for autoimmune and oncology indications.

BiotechHealthtechBrisbane, US

Stephen Brady(Director)inMatthew Angel(Executive Officer, Director)Nicholas Maestas(Executive Officer)inThomas W. Dubensky, Jr.(Executive Officer, Director)Thomas Woiwode(Director)Geoffrey Nichol(Director)

Co-investorsF-F-Prime CapitalLALAVLILilly Asia VenturesNENew Enterprise Associates (NEA)QUQuan CapitalVEVersant Ventures

Takeda is a global pharmaceutical company that develops medicines and treatments for patients, focused on advancing science, technology, and partnerships to create new standards of care.

BiotechHealthtechTokyo, JP

CDClaudia D'Augusta(Executive Officer)inEBEduardo Bravo Fernandez de Araoz(Executive Officer, Director)Marie Paule Richard(Executive Officer)inWilfried Dalemans(Executive Officer)

BoardJune Almenoff(Director)Russell Greig(Director)

Co-investorsKLKleiner PerkinsRHRho VenturesYSYsios CapitalBRBrightlands Venture PartnersKRKreos Capital

Timely offers automatic time tracking software with a Microsoft Teams integration that captures time spent on meetings, calls, shared documents, and team communications.

AI & Machine LearningEnterprise SoftwareFuture of WorkSaaSOslo, NO

MMMathias Mikkelsenin

Co-investors50500 GlobalCOConcentricINInvestinorMOMovacSNSNÖ Ventures